On the other hand, tumours with overexpression or activating mutations in EGFR, such as carcinomas of the upper gastrointestinal tract, lung and mammary tissue, or glioblastomas (Birkman et al., 2016; Furnari et al., 2015; Guo et al., 2015; Huang et al., 1997; Li et al., 2008; Siegelin and Borczuk, 2014; Zhang et al., 2016), might be responsive to impairment of RAL function. This evidence concerns the gene EGFR and carcinoma.